Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,173 questions in 89 reviews · Neuromuscular
current versionsNo studies 302 · 25.7%Ungraded 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Surgery vs splint Clinical improvement ‐ Long‐term improvement: > 3 months · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | RR 2.1 [1.04, 4.24] | 3 studies · 210 participants | Moderate |
Surgery vs corticosteroid injection Function ‐ Long‐term improvement: > 3 months · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | no estimate extracted | 2 studies · 191 participants | Moderate |
Surgery vs corticosteroid injection Pain (VAS) ‐ Long‐term improvement: > 3 monthsScale: 0 to 100, higher is worse · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | no estimate extracted | 1 study · 123 participants | Moderate |
Surgery vs corticosteroid injection Health‐related quality of life ‐ Long‐term improvement: > 3 months · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery vs corticosteroid injection Adverse effects · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | RR 1.49 [0.25, 8.7] | 2 studies · 90 participants | Very low |
Surgery vs corticosteroid injection Need for surgery or secondary surgery during · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | RR 0.61 [0.25, 1.46] | 1 study · 163 participants | Very low |
Surgery vs splint Symptoms (Boston CTS questionnaire) ‐ Long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | no estimate extracted | 2 studies · 195 participants | Moderate |
Surgery vs splint Function (Boston CTS questionnaire) ‐ Long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | no estimate extracted | 2 studies · 195 participants | Moderate |
Surgery vs splint Pain ‐ Long‐term improvement: > 3 months · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery vs splint Health‐related quality of life (EQ‐5D) ‐ Long‐term improvement: > 3 months Scale: 0 to 1, higher is better · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | no estimate extracted | 1 study · 167 participants | Low |
Surgery vs splint Adverse effects · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | RR 2.11 [0.37, 12.12] | 2 studies · 210 participants | Very low |
Surgery vs splint Need for surgery or secondary surgery during · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | RR 0.03 [0, 0.21] | 2 studies · 176 participants | Moderate |
Surgery vs corticosteroid injection Clinical improvement ‐ Long‐term improvement: > 3 months · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | RR 1.23 [0.73, 2.06] | 3 studies · 187 participants | Very low |
Surgery vs corticosteroid injection Symptoms ‐ Long‐term improvement: > 3 months · people with carpal tunnel syndrome Surgical versus non‐surgical treatment for carpal tunnel syndrome (2024) · Cochrane | no estimate extracted | 2 studies · 118 participants | Very low |
Intravenous immunoglobulin vs placebo Significant improvement in disability within 6 weeks · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | RR 2.4 [1.72, 3.36] | 5 studies · 269 participants | High |
Intravenous immunoglobulin vs prednisolone Change in mean disability score on Rankin scale · patients with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | no estimate extracted | 1 study · 24 participants | Moderate |
Intravenous immunoglobulin vs prednisolone Change in mean disability score at 24 weeks or later · patients with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs prednisolone Serious adverse events · patients with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | RR 0.45 [0.04, 4.69] | 1 study · 57 participants | Moderate |
Intravenous immunoglobulin vs intravenous methylprednisolone Significant improvement in disability within 6 weeks · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | RR 1.46 [0.4, 5.38] | 1 study · 45 participants | Moderate |
Intravenous immunoglobulin vs intravenous methylprednisolone Change in mean disability score on Rankin scale · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | no estimate extracted | 1 study · 43 participants | Moderate |
Intravenous immunoglobulin vs intravenous methylprednisolone Change in mean disability score at 24 weeks or later · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | no estimate extracted | 1 study · 45 participants | Moderate |
Intravenous immunoglobulin vs intravenous methylprednisolone Serious adverse events · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | RR 4.4 [0.22, 86.78] | 1 study · 45 participants | Moderate |
Intravenous immunoglobulin vs placebo Change in mean disability score on Rankin scale · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | no estimate extracted | 3 studies · 90 participants | High |
Intravenous immunoglobulin vs placebo Change in mean disability score at 24 weeks or later · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | no estimate extracted | 1 study · 117 participants | Moderate |
Intravenous immunoglobulin vs placebo Serious adverse events · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | RR 0.82 [0.36, 1.87] | 3 studies · 315 participants | Moderate |
Intravenous immunoglobulin vs plasma exchange Significant improvement in disability within 6 weeks · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs plasma exchange Change in mean disability score on Rankin scale · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs plasma exchange Change in mean disability score at 24 weeks or later · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs plasma exchange Serious adverse events · people with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | no estimate extracted | 1 study · 20 participants | Ungraded |
Intravenous immunoglobulin vs prednisolone Significant improvement in disability within 6 weeks · patients with CIDP Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy (2024) · Cochrane | RR 0.91 [0.5, 1.68] | 1 study · 29 participants | Moderate |
Alpha‐lipoic acid vs placebo Change in neuropathy symptoms · people with DPN Alpha‐lipoic acid for diabetic peripheral neuropathy (2024) · Cochrane | no estimate extracted | 1 study · 330 participants | Moderate |
Alpha‐lipoic acid vs placebo Change in impairment · people with DPN Alpha‐lipoic acid for diabetic peripheral neuropathy (2024) · Cochrane | no estimate extracted | 1 study · 245 participants | Low |
Alpha‐lipoic acid vs placebo Change in any validated quality of life score · people with DPN Alpha‐lipoic acid for diabetic peripheral neuropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Alpha‐lipoic acid vs placebo Complications of DPN · people with DPN Alpha‐lipoic acid for diabetic peripheral neuropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Alpha‐lipoic acid vs placebo Adverse events leading to cessation of treatment · people with DPN Alpha‐lipoic acid for diabetic peripheral neuropathy (2024) · Cochrane | RR 1.48 [0.5, 4.35] | 3 studies · 1090 participants | Moderate |
Summary of findings: corticosteroid and local anaesthetic injection (CS+LA) vs local anaesthetic injection (LA) Pain: VAS(0 to 100; a lower score indicates less pain) (change from baseline and final values) · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | 2 studies · 157 participants | Low |
Summary of findings: ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) vs non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) Adverse events · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | RR 0.42 [0.12, 1.39] | 2 studies · 116 participants | Low |
Summary of findings: plantar‐incision neurectomy (PN) vs dorsal‐incision neurectomy (DN) Pain: VAS(0 to 100; lower score indicates less pain) · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: plantar‐incision neurectomy (PN) vs dorsal‐incision neurectomy (DN) Function: restrictions in daily activities (4‐item Likert scale) · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: plantar‐incision neurectomy (PN) vs dorsal‐incision neurectomy (DN) HRQoL · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: plantar‐incision neurectomy (PN) vs dorsal‐incision neurectomy (DN) Satisfaction: 4‐item Likert scale (dichotomised into satisfied and dissatisfied) · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | RR 1.06 [0.87, 1.28] | 1 study · 73 participants | Low |
Summary of findings: plantar‐incision neurectomy (PN) vs dorsal‐incision neurectomy (DN) Adverse events · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | RR 0.95 [0.32, 2.85] | 1 study · 75 participants | Low |
Summary of findings: corticosteroid and local anaesthetic injection (CS+LA) vs local anaesthetic injection (LA) Function: · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | 2 studies · 157 participants | Low |
Summary of findings: corticosteroid and local anaesthetic injection (CS+LA) vs local anaesthetic injection (LA) HRQoL: EQ‐5D (0 to 1; a higher score indicates improved HRQoL) (final values) · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | 1 study · 122 participants | Moderate |
Summary of findings: corticosteroid and local anaesthetic injection (CS+LA) vs local anaesthetic injection (LA) Satisfaction: Modified Johnson Scale (dichotomised into satisfied and dissatisfied) · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | RR 1.08 [0.63, 1.85] | 1 study · 35 participants | Low |
Summary of findings: corticosteroid and local anaesthetic injection (CS+LA) vs local anaesthetic injection (LA) Adverse events · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | RR 9.84 [1.28, 75.56] | 2 studies · 157 participants | Very low |
Summary of findings: ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) vs non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) Pain: VAS (0 to 100; a lower score indicates less pain) (final values) · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | 2 studies · 116 participants | Moderate |
Summary of findings: ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) vs non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) Function: · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | 2 studies · 116 participants | Moderate |
Summary of findings: ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) vs non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) HRQoL · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) vs non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) Satisfaction: 4‐point Likert scale (dichotomised into satisfied and dissatisfied) · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | RR 1.71 [1.19, 2.44] | 2 studies · 114 participants | Low |